Piramal Pharma Limited — Others, 30-07-2025: Shareholders meeting

Piramal Pharma's 5th Annual General Meeting saw all proposed resolutions approved by shareholders. Key outcomes include the adoption of the audited financial statements for the fiscal year ended March 31, 2025, and the declaration of a final dividend of ₹0.14 per equity share. Shareholders also approved the re-appointment of Ms. Nandini Piramal and other director/auditor appointments. Importantly, the company received approval to issue Non-Convertible Debentures through private placement, which enhances its financial flexibility for future operations and growth initiatives. This signals continued governance and strategic financial planning.